Treatment of human GSC-grafted mice with viral vector-delivered TLX shRNA or nanovector-delivered TLX siRNA inhibits tumour development and prolongs survival. Moreover, we identify TET3 as a ...

Figure 1: Sequence-independent CNV suppression by siRNA through TLR3. Figure 2: CNV suppression by siRNA is mediated by IFN-γ and IL-12. We proposed that C terminus dimerization of TLR3 ECDs ...

The success of this methodology depends on choosing the proper target sequence within the gene of interest and proper design of the siRNA oliginucleotides. PAGE purification of your oligonucleotides ...

This prevents the cell from making proteins from that specific genetic sequence. "If you think of the cell as being a huge block of text in a word processing program, siRNA is like a search and ...

In principle, any gene can be silenced by a synthetic siRNA with a complementary sequence. This makes them an important tool for drug targeting and validating gene function. There have been many ...

"Introduction of the modification at a single location achieved the desired effect, enabling a highly flexible sequence design of siRNA." Chemically modified siRNAs using this modification are ...

In the current study, use of a commonly used control siRNA sequence called GFP siRNA, which has only a minimal capacity to activate the immune system, clearly showed the striking difference between ...

SiRNA designed to target the human VEGF gene promoter revealed a putative candidate for transcriptional gene silencing. However, mutation or deletion of the target site demonstrated that the observed ...

"Introduction of the modification at a single location achieved the desired effect, enabling a highly flexible sequence design of siRNA." Chemically modified siRNAs using this modification are ...

However, depending on the structure and sequence of a siRNA and how it is delivered, it may induce a potent innate immune response in humans, stimulating the release of inflammatory chemicals such ...

The double-stranded RNAi agent outlined in claims 1 and 2 of the patent share an essentially identical siRNA sequence but differ in terms of chemical modification, with the sense strand being ...

GalNAc-siRNA is a stable conjugate formed by the covalent conjugation of GalNAc to the 3' end of the sense sequence of siRNA. GalNAc can bind to the highly expressed sialic acid receptors in the liver ...